The post thrombotic syndrome is one of the most dreaded complications of proximal deep vein thrombosis. This syndrome leads to pain and suffering with leg swelling, recalcitrant ulceration and venous claudication which greatly impairs mobility and quality of life. The prevalence can be high in patients with iliofemoral venous involvement particularly in the setting of a proximal venous stenosis, such as occurs in May Thurner syndrome. Anticoagulation alone does not reduce the likelihood of this outcome. Compression therapy may be effective but garment discomfort limits its implementation. Pharmacomechanical thrombectomy, which combines catheter-directed thrombolysis with mechanical thrombus dissolution, provides an attractive treatment strategy for such patients. The rationale and delivery of pharmacomechanical thrombectomy, including patient selection and adjunctive antithrombotic therapy, will be reviewed in addition to tips and tricks for managing difficult patient scenarios.
Introduction: epidemiology of venous thrombosis
Venous thromboembolism (VTE) is a common disease with an average annual incidence of 104-183 per 100 000 person-years (Heit, 2015) . Incidence rates increase significantly with age in both genders (Silverstein et al, 1998) . Despite increased awareness and better strategies for VTE prophylaxis, the incidence has not declined over time; moreover, it is expected that it will double between 2006 and 2050 due to the aging population (Deitelzweig et al, 2011) . Post-thrombotic syndrome (PTS) is the most common chronic complication of deep vein thrombosis (DVT) and leads to protracted morbidity and impaired quality of life (Kahn et al, 2014a) . PTS resulting from venous valvular insufficiency and outflow obstruction may produce symptoms ranging from mild leg pain and oedema to severe debilitating pain, oedema and skin ulceration. Diseasespecific quality of life scores correlate directly with increased PTS severity (Kahn et al, 2002 (Kahn et al, , 2008a and are similar to other chronic conditions, such as arthritis, chronic lung disease and diabetes (Kahn et al, 2008a) . PTS also increases health care costs by up to 50% (Bergqvist et al, 1997; Macdougall et al, 2006; Guanella et al, 2011) , and costs escalate with increased severity of the syndrome (Ramacciotti et al, 2006) .
Following leg DVT, the prevalence of PTS is high despite appropriate anticoagulant therapy. Proximal DVT carries a higher risk compared to distal infrapopliteal 'calf' DVT. As such, patients with iliac venous thrombosis carry the highest risk. PTS affects up to 60% of patients within 2 years of the initial thrombotic event (Ashrani & Heit, 2009; Kahn et al, 2014a) , and this percentage continues to rise for the next two decades (Mohr et al, 2000; Kahn et al, 2014a) . Severe PTS with venous claudication and recalcitrant ulceration may impact up to 30% of patients (Prandoni et al, 1996; Brandjes et al, 1997; Stain et al, 2005) .
A major limitation to understanding the epidemiology of PTS following DVT stems from an inconsistency of PTS definition across studies. The Villalta score (Villalta et al, 1994) is a validated clinical questionnaire designed to provide a consistent definition and scoring tool for disease specific severity assignment. This tool assigns points (0-3) in five patient-rated and six clinician-rated areas. Score values correlate with quality of life measures. PTS is said to be present for scores exceeding five points. In a large prospective study of 387 patients with incident DVT, 43% developed PTS over the ensuing 24 months (Kahn et al, 2008b) , and 16% had severe PTS, defined as a high Villalta score (>14 points) or skin ulceration. Independent predictors of PTS include patient age at time of thrombosis, body mass index, female gender and proximal (common femoral or iliac vein) DVT location. Others have found similar incidence rates and predictors. For example, in a prospective study of 111 patients, the incidence of PTS was 46% at 3 months (Tick et al, 2010) . However, this prospective cohort study found that involvement of proximal veins was the only independent predictor of PTS [relative risk (RR): 2Á3; 95% confidence interval (CI): 1Á0-5Á6] (Tick et al, 2010) .
Venous hypertension caused by proximal obstruction and valvular incompetence, either alone or in combination, appears to play a key role in the pathophysiology of PTS. Venous obstruction alone carries a 50% increased risk of PTS (RR 1Á56; 95% CI 1Á01-2Á45). This risk is increased when venous obstruction is combined with valvular incompetence (RR 1Á69; 95% CI 1Á23-2Á32) (Prandoni et al, 2005; Roumen-Klappe et al, 2005; Tick et al, 2010) . These findings have led to the hypothesis that early thrombus resolution while restoring venous patency improves outcomes.
Historic perspective and progression of thrombus removal
Strategies to relieve lower extremity venous outflow obstruction were initially limited to surgical thrombectomy. The first procedure was reported by Laewen (1937) , who successfully performed in a patient with phlegmasia cerulea dolens. Surgical thrombectomy was widely adopted in the 1960s but fell into disfavor due to high rate of thrombosis recurrence, and poor long-term results. Lansing and Davis (1968) reported their 5-year follow-up of 39 patients. Of these, 10 patients died early in the follow-up, two due to pulmonary embolism (PE). Hospital stays were prolonged and bleeding rates were high. Indeed, nearly all patients (92%) required a transfusion. Long-term outcomes in survivors included a high rate of PTS. Postoperative venography revealed gross venous valvular incompetence of the operated venous segments. Surgical thrombectomy was thereafter reserved for cases of phlegmasia. Of note, anticoagulation was limited to intravenous heparin delivered in the hospital, arguably a major limitation of that era. More encouraging outcomes have been reported in recent decades (Plate et al, 1997) .
Systemic thrombolytic therapy was initially used as treatment for lower extremity DVT in the late 1960's. Several small randomized trials compared intravenous streptokinase to anticoagulation alone. A meta-analysis of seven trials (Ng & Rivera, 1998) found that patients treated with streptokinase developed lower rates of PTS [summary odds ratio (SOR), 0Á40; 95% CI, 0Á18-0Á88], but at a cost of increased bleeding (SOR, 3Á78; 95% CI, 1Á26-11Á32). Streptokinase has been since abandoned due to adverse side effects and immunogenicity limiting therapy to a single exposure.
The long term impact on venous physiology following systemic thrombolysis has been assessed by phlebography (Arnesen et al, 1982) . This study assessed venous physiology in 35 patients randomized to thrombolytic therapy plus anticoagulation verses anticoagulants alone. At a mean follow up of 6Á5 years, 7 of 18 patients randomized to thrombolysis had normal venous function. In contrast, all patients assigned to heparin had postphlebitic physiology. Moreover, symptom-free survival was much higher in patients treated with thrombolysis (76%) compared to anticoagulants alone (33%). There was no difference in DVT recurrence rates, however those patients suffering a recurrence had worse clinical outcomes.
In a five-arm treatment trial (n = 250), anticoagulation was compared with four thrombolysis strategies: systemic tissue plasminogen activator, systemic urokinase, loco-regional urokinase or loco-regional streptokinase. Patients receiving systemic thrombolysis had higher recanalization rates and lower PTS rates. There were no confirmed PEs (Schweizer et al, 2000) . An unacceptably high incidence of major bleeding (28%) limited the enthusiasm for this approach. Locoregional delivery, which involved dorsal foot venous cannulation, was found to be cumbersome and not widely adopted.
The first report of catheter directed thrombolysis (CDT) was published by Okrent et al (1991) . This technique combined local delivery of thrombolytic agents directly into the thrombus (over 68 h) with adjuvant balloon angioplasty to treat residual webbing and was promptly popularized (Okrent et al, 1991) . Molina et al (1992) described their experience using intra-thrombus urokinase delivery from an internal jugular venous approach in 11 patients with acute or sub-acute thrombosis, seven with phlegmasia cerulean dolens. Thrombus resolution was 95% at a median therapeutic duration of 2Á9 days (range 2-4 days). As in the study reported by Okrent et al (1991) , residual stenoses were treated with balloon angioplasty. All patients reported symptomatic improvement. Neither major bleeding nor PE rates were reported. Four patients had an inferior vena cava filter (IVCF) placed in conjunction with the procedure (Molina et al, 1992) . The success of these early reports underscored the importance of pharmacological thrombus removal as well as treating the underlying venous stenosis. Semba and Dake (1994) were the first to incorporate stenting to the venoplasty procedure using Wallstents (Boston Scientific, Natick, MA, USA) for this purpose.
In 1997, Bjarnason et al established the inverse relationship between symptom duration and technical success rates. If treated within 1 week of symptom onset, technical success was 86% compared to 79% for symptoms of 1-2 weeks duration, and 33% if symptoms were more than 4 weeks prior to initiation of CDT (Bjarnason et al, 1997) . These investigators also pioneered the use of mechanical thrombectomy (surgical or endovascular) to shorten thrombolysis infusion times (applied in 17 patients). The 2-year primary and secondary patency rates underscored the complexity and extent of disease of patients studied (Bjarnason et al, 1997) .
The first multicentre registry evaluating treatment outcomes of CDT across sites included 63 centres across the USA (Mewissen et al, 1999) . Urokinase was delivered to 312 limbs, with either acute (≤10 days) or chronic thrombosis (>10 days) involving venous segments from the inferior vena cava to the popliteal veins. The overall primary patency rate was 65% at 6 months and 60% at 12 months. Interventions for femoral-popliteal DVT had lower 1-year patency rates (47%) compared to iliofemoral DVT (64%; P < 0Á01).
Adjunctive stent placement, performed in 33% of the patients, yielded higher patency rate at 1 year (74% vs. 53%; P < 0Á001).
A thrombus burden scoring tool was developed to quantify the degree of thrombotic obstruction and the efficacy of thrombolysis. With this tool, venous segments were initially scored on a scale of 0-2 based on patency (0 = open vein, 1 = partially occluded vein, 2 = totally occluded vein). This grading tool has subsequently evolved to express the percentage of thrombolysis accomplished (grade I = <50%, grade II = 50-90%, grade III = complete thrombolysis) and has been useful for inter-study comparisons (Mewissen et al, 1999) .
In this registry, loco-regional thrombolysis delivery (n = 60) compared to traditional CDT (n = 252) resulted in longer treatment times (67Á8 h vs. 48Á0 h; P < 0Á001), greater drug use and lower efficacy (Mewissen et al, 1999) . Complete lysis (grade III) was obtained in 33% of the CDT group compared to 22% in the locoregional group (P < 0Á03). Major bleeding occurred in 11% including access site bleeding (21%), retroperitoneal haematoma (13%) and musculoskeletal, gastrointestinal or genitourinary sites (28% combined). Two patients died (mortality rate, 0Á4%), one from PE and one from intracranial haemorrhage. Following this published experience, loco-regional delivery of thrombolysis was largely abandoned.
The first randomized controlled trial enrolled 35 patients to receive either CDT with streptokinase compared to anticoagulation alone (Elsharawy & Elzayat, 2002) . CDT improved both venous patency rates at 6 months (72% vs. 12%; P < 0Á0001) and venous insufficiency rates (41% vs. 11%, P = 0Á04) (Elsharawy & Elzayat, 2002) . Despite small subject numbers, these study results paved the way for additional randomized trials. The larger CaVenT trial randomized 118 patients to either CDT plus anticoagulation vs. anticoagulation alone (plus compression stockings). The 6-month follow-up results confirmed the technical success of the intervention and demonstrated superior clinical outcomes with higher patency rates for those patients randomized to CDT [64% vs. 36%; Absolute risk reduction (ARR) 28Á2% 95% CI: 9Á7%-46Á7%; P = 0Á004] (Enden et al, 2009 ). CDTassociated major bleeding was reasonably low at 4% and there were no PEs. Although outflow obstruction assessed by venous plethysmography was less frequent in the CDT group (20% vs. 49%; ARR 29% 95% CI: 20Á0% to 38Á0%; P = 0Á004), there was no difference in clinical PTS prevalence at 6 months (Enden et al, 2009) . And yet, the 2-year followup revealed lower PTS favouring CDT, with an ARR of 14Á4% (95% CI 0Á2-27Á9) with a number needed to treat of only 7. Trial criticism included the limited use of mechanical thrombectomy and adjunctive stenting (16Á7%) (Enden et al, 2012) .
The Cochrane collaboration group performed a meta-analysis of thrombolysis (Watson et al, 2014) that included 17 studies involving any venous segment from the iliac to the infrapopliteal veins. Study heterogeneity in terms of thrombolytic agent used, dose and route of administration was a methodological limitation precluding direct comparisons of specific outcomes. Patency rates were however higher in the thrombolytic group (RR: 2Á48; 95% CI 1Á35-4Á57, P = 0Á004) at the cost of increased bleeding (RR: 2Á23; 95% CI 1Á41-3Á52, P = 0Á0006; 9% vs. 4%). PTS occurred less frequently in patients receiving thrombolysis (RR 0Á64; 95% CI 0Á52-0Á79, P < 0Á0001) with a number needed to treat of only 5. Only four studies reported PTS outcomes. Only two randomized trials were included (Elsharawy & Elzayat, 2002; Enden et al, 2012) .
In the Thrombus Obliteration by Rapid Percutaneous Endovenous Intervention in Deep Venous Occlusion (TOR-PEDO) trial, 183 patients were randomized to pharmacomechanical thrombectomy (PMT) versus anticoagulation alone. In this trial, devices included AngioJet (Bayer Healthcare, Warrendale, PA, USA), Trellis (Bacchus Vascular, Santa Clara, CA, USA) and manual aspiration. Therapy was supplemented with CDT if there was more than 30% residual luminal thrombus. After 6 months of follow-up, PTS developed less frequently (3Á4% vs. 27Á2%; P < 0Á001) and was less severe in the intervention group compared to anticoagulation alone. Although treatment duration for the PMT was not provided, hospital stays were shorter for the interventional group (Sharifi et al, 2010) .
Current treatment options and technique
Since its initial description 25 years ago (Okrent et al, 1991) , there has been significant progress made in endovascular removal of acute thrombosis of the iliac and femoral veins. First, catheters were initially placed from a jugular vein approach. When the iliac veins and the femoral veins were involved, infusion catheters were first placed in the iliac veins for overnight infusion and then advanced to more distal thrombi as thrombolysis progressed. The unidirectional nature of venous valves often presented a technical and timeconsuming challenge for catheter advancement (Bjarnason et al, 1997; Mewissen et al, 1999) . The transition to popliteal venous access meant that the entire thrombus could be infused at the same time, thus greatly accelerating procedural times. Second, it became common practice to place a separate infusion system (simultaneously) from the ankle in cases of where thrombi extended into the popliteal and calf veins to improve femoral venous inflow (Fig 1) . The ipsilateral popliteal vein is currently the preferred access site with access into the posterior tibia vein when there is involvement of the popliteal and calf veins at our institution. Third, CDT by itself is a slow and expensive procedure, which takes an average of 3 days during which time the patient requires intensive care unit stay for monitoring purposes (Bjarnason et al, 1997; Mewissen et al, 1999) . Mechanical devices were introduced with the objective to improve procedural times, decrease the amount of thrombolytic agent needed and decrease cost. These mechanical devices are low profile and provide physical fragmentation and aspiration of thrombotic material. In most cases mechanical thrombectomy alone is insufficient and requires thrombolysis delivery (CDT). This is often referred to as pharmacomechanical thrombectomy (PMT) (Fig 2A, B) . Our approach is to treat with PMT first and if there is significant residual thrombus, infusion catheters are placed with overnight thrombolytic infusion. We strive for complete thrombus resolution (open-vein hypothesis), meaning removal of as much residual mural thrombus as possible to limit valvular injury.
A multicentre registry evaluated the safety and efficacy of AngioJet Thrombectomy (Boston Scientific Corporation, Marlborough, MA, USA) in 329 patients with lower extremity DVT (Garcia et al, 2015) . The use of this device reduced the average treatment time by 75% (18Á3 h vs. 72 h for earlier reports) (Bjarnason et al, 1997; Mewissen et al, 1999) . In cases where no additional thrombolytic therapy was required, treatment duration was, on average, 1Á4 h! For cases where CDT was used, treatment times averaged 41 h. In this registry of 329 patients from 32 sites there was one severe complication, an acute renal failure. Major bleeding occurred in 12 patients (3Á6%) (Garcia et al, 2015) .
Patient selection
Careful patient selection is central to improving outcomes while minimizing complications. It is important to first review the contraindications for thrombolysis. Thereafter, patient characteristics associated with higher success rate are reviewed. Whereas the main goal of CDT is to reduce the risk of PTS, patients with a short life expectancy or those who are non-ambulatory are unlikely to benefit from this treatment. Conversely, phlegmasia cerulea dolens or extensive inferior vena cava thrombosis with renal vein compromise are indications with a favourable risk benefit ratio. A careful discussion of the risks and benefits with the patient, paying especial attention to patient preferences should guide decision-making (Fig 3) .
Predictors of complications
Bleeding risk. Although CDT utilizes a lower dose of thrombolytics, there are no direct comparison trials with systemic thrombolysis to confirm a safety benefit. It is generally accepted that the same contraindications are applicable for both (Table I) . Patient-specific risk assessment is important before treatment is initiated. Inclusion and exclusion variables should be considered as guidance, not rigid criteria. Careful consideration of the benefits and risks should be carefully considered. This is best done with input from all stakeholders in the patient care team. The patient then needs to be presented with the options for discussion and final decision-making.
Operator and institution-specific procedural volumes play an important role in outcomes. In an analysis of the Nationwide Inpatient Sample, mortality rates were lower at high volume centres compared with low volume centres (0Á6% vs. 1Á5%; OR, 2Á40; 95% CI, 1Á04-5Á43; P = 0Á04). This included a trend toward lower intracranial haemorrhage (0Á4% vs. 1%; OR, 2Á62; 95% CI, 0Á93-7Á29; P = 0Á07) (Jarrett et al, 2015) . These differences are probably explained by both operator experience and institution-specific variables, such as staffing, protocols and infrastructure.
Predictors of successful thrombolysis
A number of patient-specific variables are known to directly impact clinical outcomes. First, venous segment-specific This drawing depicts the patient in prone positon with thrombus extending from the left ankle to the proximal common iliac vein. Introducer sheath has been placed in the left posterior tibial vein (PTV) at the ankle and an infusion catheter has been positioned through it, reaching up to the popliteal vein or above. This infusion catheter allows for lytic infusion into the PTV and the popliteal vein. A second introducer sheath has been placed in the left popliteal vein and through this a separate infusion catheter has been positioned which spans over the remaining thrombus up to the common iliac vein. This allows for simultaneous infusion into the entire thrombus.
thrombus location is an important consideration. Patency rates were higher in patients with iliofemoral (64%) compared with femoropopliteal venous segments (47%; P < 0Á01) (Mewissen et al, 1999) .
Second, thrombus acuity also appears to be an important variable. The guidelines recommend considering CDT or PMT in patients who have been symptomatic for less than 14-21 days (Jaff et al, 2011; Meissner et al, 2012) . In the Venous Registry, which included 312 patients undergoing thrombolysis with urokinase, the likelihood of complete lysis was higher (34%) when the symptoms occurred less than 10 days before the procedure, compared to 19% beyond 10 days (P < 0Á01) (Mewissen et al, 1999) . In the CaVenT trial, most patients were lysed within 6 days of the symptom onset (Enden et al, 2009 ). Nevertheless, predicting thrombus age can be difficult. Symptom onset may not be the best indicator of thrombosis initiation. Tools capable of accurately determining thrombus age would be useful clinically. One promising modality utilizes magnetic resonance imaging (MRI) technology, which exploits haemoglobin desaturation with methaemoglobin formation over time to assess thrombus age. With this technology, T1 signal differences can distinguish methaemoglobin (Fe +3 ) from haemoglobin (Fe +2 ), which forms within 8 h of thrombus incorporation. This signal difference is maximal by 3 weeks and decays over 6 months, allowing distinction between acute and chronic thrombosis (Obernosterer et al, 2002; Moody, 2003) . Other investigators have used mouse models using MRI to assess thrombus age and thrombolysis efficacy (Saha et al, 2013; Andia et al, 2014) . This method may also be helpful to differentiate acute or chronic thrombosis, a common diagnostic problem (Tan et al, 2014) .
Third, procedural success predicts patency rates at 12 months. In patients who achieved complete lysis (grade III), 79% of the veins were patent 12 months after the procedure compared to only 32% of those with grade I lysis (Mewissen et al, 1999) . Optimal patency rates were found in patients with iliac DVT and complete lysis. At 1 year, patency rates were 85% in these patients . This may provide the rationale for continuing CDT following less than complete thrombus resolution following the mechanical thrombectomy.
Fourth, stenting of residual venous stenosis, particularly in the iliac veins, has been shown to improve patency rates. Indeed, one of the main criticisms of the CaVenT study was the low frequency of stent use (Enden et al, 2012) . Most patients will require stenting of the iliac veins as part of the treatment if a flow-limiting lesion is identified. At our institution we place stents in combination with CDT for all iliac and common femoral vein obstructions that appear haemodynamically significant. This approach is used in three quarters of our treated patients. However, stenting distal to iliac venous segments has not been successful and is discouraged (Mewissen et al, 1999) .
Anticoagulation
There is no consensus regarding periprocedural parenteral anticoagulation management. The Society of Interventional Radiology (SIR) Quality Improvement Guideline recommends intravenous unfractionated heparin targeting an activated partial thromboplastin time (aPTT) at 1Á2-1Á7 times control (Vedantham et al, 2014) . The CaVenT investigators adopted this regimen, treating patients with heparin for at least 8 h before the procedure (Enden et al, 2012) . Other investigators advocate targeting an aPTT of 60-100 s during the procedure, usually with infusion of unfractionated heparin at 8-10 units/kg/h (Sharifi et al, 2015) . It is our practice to give intravenous heparin at a dose of 500 units/h through the introducer sheath side arm while monitoring the aPTT every 6 h, targeting values less than 60 s. 
Procedural care
Monitoring clinical and laboratory parameters, including haemoglobin, haematocrit, aPTT and fibrinogen, is recommended. It is not uncommon to see slight drop (~10%) in haemoglobin during thrombolysis. This is not related to bleeding. Monitoring fibrinogen levels during thrombolysis is controversial. A clear correlation between fibrinogen levels and bleeding complications has not been demonstrated. It is our practice to monitor fibrinogen levels every 12 h and considering stopping thrombolysis if values drop below 1 g/l (3 lmol/ l). Alternatively, cryoprecipitate can be given while continuing the thrombolysis infusion. There are no guidelines regarding the frequency of laboratory monitoring. It is our practice to measure haemoglobin, haematocrit and platelets every 6 h during thrombolysis; creatinine is assessed every 12 h.
The duration of the thrombolytic infusion is directly associated with bleeding risk. Limiting infusion times appears to mitigate this risk. We try to avoid extending the thrombolytic infusion beyond 48 h unless extensive thrombus burden or phlegmasia cerulean dolens require continued therapy. Under these circumstances, the infusion can be extended to 72 h.
Maintaining adequate hydration, limiting contrast volumes, use of low or iso-osmolar nonionic contrast agents and avoiding concurrent nephrotoxins (nonsteroidal antiinflammatory drugs) reduces the likelihood of contrastinduced nephropathy. These factors are particularly important for patients at risk for renal injury. Risk factors for nephrotoxicity include advanced age (>70 years), chronic kidney disease and diabetes mellitus. Sterile techniques to prevent catheter related infections, and premedication with steroids and antihistaminics in patients with contrast allergies are also warranted (Vedantham et al, 2014) . Mechanical thrombectomy can cause significant haemolysis, which may lead to renal impairment. Providers should therefore watch for haemoglobinuria, which must be distinguished from haematuria by urinalysis. This finding should prompt an algorithm for renal protection. Post procedure care
Anticoagulation. Prompt re-initiation of therapeutic anticoagulation is required following the intervention. In the CaVenT trial, low molecular weight heparin (LMWH) was restarted 1 h after the procedure, along with warfarin targeting an international normalised ratio of 2-3. These investigators did not use antiplatelet agents (Enden et al, 2012) . There are no direct comparisons between vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs) for prevention of PTS. Patients undergoing CDT were excluded from participating in the main DOAC trials. These newer anticoagulants were used safely and effectively in a interventional registry (Sharifi et al, 2015) . With the ability to inhibit clot-bound thrombin or factor Xa, these investigators postulated that the DOACs may promptly reduce thrombus volumes while minimizing venous valvular damage. Therapeutic DOACs were started 2 h after the procedure, in addition to antiplatelet therapy. Antiplatelet agents were then continued for 1 month. In this registry, PTS occurred in 5Á5% of 127 patients followed for 22Á5 months. A previous study of PMT by the same group reported a PTS incidence of 6Á8% when treated with warfarin (Sharifi et al, 2010) . There were no reported in-hospital bleeding complications in this report. DOACs have the potential advantage of more predictable anticoagulant delivery compared to warfarin with no dose adjustment, no food interactions, no monitoring and few drug interactions (Chitsike et al, 2012) . Factors such as cost and patient preferences should be taken into consideration when deciding on the outpatient management. Duration of anticoagulation should follow the guidelines, which are largely based on the presence of provoking factors (Kearon et al, 2016) . Cancer, prior history of VTE and the presence of a 'strong' thrombophilia should also be considered in this decision-making. Strong thrombophilias have Table I . Absolute and relative contraindications for systemic thrombolytics.
ACCP
AHA SVS Absolute Previous intracranial haemorrhage X X X Ischaemic stroke within 3 months X X X Recent spinal or intracranial surgery X X X Recent head trauma with fracture or brain injury X X X Active bleeding X X X Bleeding diathesis X X X Structural intracranial disease X X Known malignant intracranial neoplasm X X Suspected aortic dissection X Relative Pregnancy X X X Systolic BP > 180 or diastolic BP > 110 X X X Recent surgery* (<2-3 weeks) X X X Ischaemic stroke more than 3 months ago X X Traumatic or prolonged (>10 min) cardiopulmonary resuscitation X X Age > 75 years X X Current anticoagulation X X Recent extracranial bleeding (within 2-4 weeks) X Recent invasive procedure X Pericarditis or pericardial effusion X Diabetic retinopathy X Low body weight (<60 kg) X Non-compressible vascular puncture sites X Chronic severe and poorly controlled hypertension X Recent internal bleeding (2-4 weeks) X Dementia X Endocarditis or intracardiac thrombus X Thrombocytopenia <80 9 10 9 /l X Contraindication for anticoagulation X Major trauma X Known left to right cardiac shunt X Suspected septic thrombus X ACCP, American College of Chest Physicians (Kearon et al, 2016) ; AHA, American Heart Association (Jaff et al, 2011); BP, blood pressure; SVS, Society for Vascular Surgery (Meissner et al, 2012) . X: Supported by the guideline as a contraindication for thrombolytics. *For AHA and SVS major surgery is a contraindication, other surgeries need to be individually assessed.
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been defined as antiphospholipid antibody syndrome, homozygous or compound heterozygous F5 R506Q (factor V Leiden) or F2 (prothrombin) G20210A mutations, protein C, protein S or antithrombin deficiencies. Whether the severity of underlying disease or obstruction of unstented venous segments should add to this decision is not clear.
Antiplatelet agents. The addition of antiplatelet agents to the antithrombotic regimen has not been evaluated in randomized trials. As early as 1992, Molina et al added dipyridamole to anticoagulation for the first 6 months (Molina et al, 1992) . In a subgroup analysis of the TORPEDO trial (Sharifi et al, 2012) , patients receiving aspirin had a 37% risk reduction of PTS (RR 0Á37, 95% CI 0Á19-0Á74, P = 0Á006). Several investigators add antiplatelet agents to the anticoagulation regime, especially if the patients have received a stent. Aspirin 81 mg/ day added to anticoagulant therapy is a common practice (Sharifi et al, 2015) . Based on a porcine model of iliac venous stenting, which didn't show benefit to adding either aspirin or clopidogrel therapy (McBane et al, 2008) , it has been our practice to avoid antiplatelet agents unless there is an additional cardiovascular indication prompting their use.
Compression. The largest randomized control trial on compression stockings (Kahn et al, 2014b) failed to demonstrate a reduction in the risk of PTS with the use of graded compression stockings. However, these patients did not receive CDT and only one-third of the subjects had DVT involving the iliac or common femoral veins. Most of the studies on CDT have included compression stockings as the standard of care (Sharifi et al, 2010; Enden et al, 2012) . Due to the low complication rate and the potential for benefit, it is our practice to prescribe knee high compression stockings, 30-40 mm Hg in weight. The patient is instructed to wear the stockings during the daytime when ambulatory for 2 years, particularly if swelling persists. With skin changes, such as lipodermatosclerosis, or prior ulceration, this recommendation is firm. We typically prescribe 2-3 pairs at a time and stockings should be renewed at 3-month intervals given the durability of the elastic.
Pregnancy. Iliofemoral DVT occurring during pregnancy can be particularly challenging to manage. It is our approach to manage pregnancy-associated DVT conservatively with LMWH, monitored regularly and dose adjusted for changes in weight. Anti-Xa levels are targeted to the therapeutic range. Compression therapy is used to manage oedema. This is a multidisciplinary effort, working in close conjunction with high risk obstetric colleagues. Following delivery, once haemostasis is secured, we would then entertain iliac venous recanalization depending on patient symptoms. In the absence of life-or limb-threatening phlegmasia cerulean dolens, we would not subject mother and fetus to radiation, contrast and fibrinolysis needed to accomplish CDT during pregnancy.
It is equally challenging to know how to best manage patients with a previously placed venous stent who then later become pregnant. Jorgensen et al (2013) reported the results of 45 pregnancies in woman who received CDT prior to the pregnancy. More than half had been treated with an iliac stent. At the onset of subsequent pregnancy, each patient was prescribed LMWH either at a prophylactic or therapeutic dose. Only one of the pregnancies was complicated by VTE recurrence. There were no adverse events involving the stented veins. Deliveries were induced at 38 weeks (Jorgensen et al, 2013) .
Management of complications.
Major bleeding is a dreaded complication of CDT/PMT and should be addressed promptly with anticoagulant reversal and control of the bleeding source where possible. Access site haematomas are by far the most common bleeding complications. For small haematomas or slow oozing around the introducer sheath, observation alone is often appropriate. If bleeding becomes more severe, the patient should be brought back to the procedural room and the introducer upsized with a larger diameter sheath. This easy manoeuvre is often sufficient to stop the bleeding. For internal bleeding, thrombolysis should be stopped with anticoagulation reversal where indicated.
Allergic reactions to contrast agents can be prevented by pre-treatment with oral methylprednisolone 32 mg given 12 h and 2 h before the procedure.
Another potentially life-threatening complication is PE, which may occur during or after the procedure. Symptomatic PE is reported in less than 1% of the cases. Ensuring adequate anticoagulation after the procedure is paramount (Vedantham et al, 2014) . Current guidelines do not support prophylactic IVCF placement prior to the procedure due to this low risk. Exceptions could include patients with poor cardiopulmonary reserve. In the TORPEDO trial, all patients undergoing PMT had an IVCF placed prior to the procedure. Filter retrieval post-procedure occurred in only 12 of 90 patients at approximately 35 days following treatment. There was one case of inferior vena cava penetration with haematoma formation. A small thrombi in the filter apex was identified in four patients at the time of removal (Sharifi et al, 2010) . Insertion site complications are uncommon due to the lower pressure in the venous system; however post-procedural site assessment is recommended. The Venous Registry reported six patients with symptomatic PE (1%) and one fatal PE during treatment (Mewissen et al, 1999) .
Our approach has been to reserve IVCF placement for patients with 'free floating' thrombi or extremely ill patients where even a small PE could be fatal. This makes up approximately 15% of our thrombolysis population. The filter is then removed at the end of the procedure.
Societal guidelines
Recent guideline (Kearon et al, 2016) recommendations favour anticoagulation alone over CTD. The American College of Clinical Pharmacy (ACCP) guideline writing committee acknowledged that the quality of the available evidence greatly reduces the strength of this recommendation, which is based on expert opinion only (grade 2C). As a caveat, the committee noted that patients most likely to benefit from CTD are those with iliofemoral DVT, low bleeding risk, onset of symptoms within prior 2 weeks and good life expectancy.
Other professional societies in USA and Europe advocate for a more prominent role of CDT. The American Heart Association (AHA) recommended CDT and PMT for limb threatening conditions (class I, level of evidence C) and discouraged systemic thrombolysis due to the increased risk of bleeding (Jaff et al, 2011) . For patients with thrombus extension despite anticoagulation (IIa C), symptomatic deterioration despite anticoagulants (IIa, B), or to prevent PTS in selected patients with low bleeding risk (IIa, B), this guideline committee endorsed endovascular treatment (Jaff et al, 2011) . Surgical thrombectomy may be considered by experienced surgeons (IIb, B). For chronic DVT (symptoms >21 days) or high bleeding risk (III B), CDT/PMT was discouraged (Jaff et al, 2011) . Similar recommendations have been published for the Society for Vascular Surgery, American Venous Forum, International Union of Angiology (IUA) and the UK National Institute for Health and Care excellence (NICE) guidelines (Meissner et al, 2012; NICE 2012; Nicolaides et al, 2013) Minor societal discrepancies highlight the need for continued research on this topic.
Implications for society
The economic burden of venous thrombosis and PTS is high. The annualized median total cost for treating PTS has been estimated at $20 569Á00; 30-fold higher compared to patients without venous disease ($680Á00/year). The direct cost of treating chronic venous disease exceeds $300 million annually in the United States. It is estimated that 200 million working days are lost annually due to skin ulceration. The risk of developing a venous ulcer increases with age. With each decade of life, this risk increases by 30%. Given that venous thrombosis is a disease of the elderly, the prevalence of this outcome is only anticipated to increase as the population of the United States ages (Phillips, 1994; Heit et al, 2001; Delis et al, 2004; Macdougall et al, 2006) . In response to these data, the use of CDT has consistently increased over the past decade in United States (Bashir et al, 2014) . In a large hospital-claims database study, patients receiving CDT had longer hospital stays with higher associated costs, raising concerns regarding future health-care expenditure for this disease. However, the real cost of PTS occurs years after the incident event with recalcitrant ulceration and venous claudication. Societal organizations and third party payers must realize that while the upfront investment of CDT greatly exceeds a strategy of anticoagulation alone, the benefits extend far beyond hospital dismissal. Enden et al (2013) attempted to address the cost -benefit relationship between these two strategies using data from the CaVenT study. They found that additional CDT was likely to be cost-effective as an alternative to anticoagulants treatment for proximal DVT and with low risk of bleeding. Ultimately, the widespread adoption of CDT will increase the immediate cost of treating iliofemoral DVT. However the long-term goals of maintaining productivity, reducing healthcare utilization in the form of wound care and associated hospitalization and the improved quality of life will ultimately benefit society.
Ongoing trials
The CAVA study (NCT00970619) will randomize 180 patients with iliofemoral DVT to conventional anticoagulation or ultrasound accelerated thrombolysis with the hypothesis that the latter will reduce the incidence of PTS and venous ulceration at 12 months. They will also include quality of life assessment and safety as secondary outcomes.
The ATTRACT study (NCT00790335) has enrolled 692 patients with symptomatic proximal DVT randomized to either PMT or anticoagulation alone. This is the largest randomized trial of PMT to date and will determine whether CDT reduces the incidence of PTS. The results are expected to be presented in March 2017.
Atypical thrombosis
Upper-extremity DVT is uncommon and accounts for only 5% of all VTE (Isma et al, 2010) . Common mechanisms include central venous cannulation with either intravenous lines, pacemakers or defibrillators, and thoracic outlet syndrome or malignancy. Like leg DVT, upper extremity DVT can lead to PTS in nearly one-third of patients (Prandoni et al, 2004; Kahn et al, 2005; Persson et al, 2006) . There are no randomized control trials comparing thrombolytics with anticoagulation in these patients. In the absence of data, the ACCP guidelines recommend anticoagulation alone (Kearon et al, 2012 (Kearon et al, , 2016 . If thrombolytics are used, they recommend CDT over systemic thrombolysis to reduce bleeding.
Treatment strategies greatly depend on the underlying mechanism. For patients with a continuing need for the offending central venous catheter, the Catheter Study supports the use of anticoagulants continued until the catheter is retrieved (Kovacs et al, 2007) . In this study, 74 cancer patients with catheter-associated DVT were successfully treated with LMWH and warfarin without the need for catheter removal. If the offending variable is a pacemaker or defibrillator wire, then a trial of anticoagulation is clearly warranted without removing the device. For patients with cancer-associated upper extremity DVT, then anticoagulation and cancer-specific therapy should be pursued. If the thrombus occurs without these variables, then 'effort thrombosis' in the setting of thoracic outlet syndrome should be considered. If these patients can be identified early (7-10 days), it is our approach to treat with CDT to remove as much thrombus as possible. Patients are then referred to vascular surgery for thoracic outlet decompression, including first rib resection and scalenectomy in selected patients. No venoplasty or stenting is pursued until outlet decompression has been completed. Patients are then anticoagulated for 3 months postprocedure (Vik et al, 2009; Lugo et al, 2015) .
For patients with cerebral venous sinus thrombosis, the recommended treatment is anticoagulation alone. For patients who have failed to improve or who deteriorate while on anticoagulants, there are case reports supporting CDT, which may improve patency rates (Qiu et al, 2015) . PMT with thrombus aspiration or disruption may have a role in treating these patients (Qiu et al, 2015) .
Conclusion
The most common complication of acute lower extremity DVT is PTS, which is estimated to affect up to 60% of all patients following DVT. Patients with venous thrombosis involving the iliac and femoral venous segments are particularly prone to develop these sequelae. Anticoagulation has limited effect on the development of PTS, but active thrombus removal from the ilio-femoral veins, using thrombolysis with or without mechanical thrombectomy, appears to be an effective way to lower the incidence and severity of PTS following acute proximal DVT. The risk-benefit ratio seems also to be in favour of early thrombus removal. Moreover, prompt thrombus removal is anticipated to reduce venous valvular destruction, improve ambulatory venous hypertension and improve calf muscle pump physiology. These combined variables ought to translate into significantly reduced rates of disabling PTS. Indeed, clinical observations of patients treated with this strategy teach us that this is a good hypothesis. The evidence in support of this treatment is eagerly awaited from ongoing randomized trials.
